CD4+ Cancer Research Results

CD4+, CD4+ T Cells: Click to Expand ⟱
Source:
Type:
CD4+ T cells are T lymphocytes that express T cell receptors (TCRs).
Majority of cancer immunotherapies focus on harnessing the anti-tumour CD8+ cytotoxic T cell response, the potential role of CD4+ ‘helper’ T cells has largely remained in the background. multifaceted role of CD4+ T cells in the anti-tumour immune response.
CD4+ T cells play a critical role in developing and sustaining effective anti-tumour immunity, even in cancer immunotherapies specifically designed to activate a CD8+ CTL response.
Scientific Papers found: Click to Expand⟱
561- ART/DHA,    Antitumor and immunomodulatory properties of artemether and its ability to reduce CD4+ CD25+ FoxP3+ T reg cells in vivo
- in-vivo, NA, NA
TumCG↓, CD4+↓, CD25+↓, FoxP3+↓, IL4↑,
560- ART/DHA,    Dihydroartemisinin shift the immune response towards Th1, inhibit the tumor growth in vitro and in vivo
- in-vivo, NA, NA
IL4↓, CD4+↓, CD25+↓, FoxP3+↓, Treg lymp↓,
562- ART/DHA,    Artesunate exerts an anti-immunosuppressive effect on cervical cancer by inhibiting PGE2 production and Foxp3 expression
- in-vivo, NA, HeLa
CD4+↓, CD25+↓, FoxP3+↓, Treg lymp↓, PGE2↓, FOXP3↓, COX2↓,
2674- BBR,    Berberine: A novel therapeutic strategy for cancer
- Review, Var, NA - Review, IBD, NA
Inflam↓, AntiCan↑, Apoptosis↑, TumAuto↑, TumCCA↑, TumMeta↓, TumCI↓, eff↑, eff↑, CD4+↓, TNF-α↓, IL1↓, BioAv↓, BioAv↓, other↓, AMPK↑, MAPK↓, NF-kB↓, IL6↓, MCP1↓, PGE2↓, COX2↓, *ROS↓, *antiOx↑, *GPx↑, *Catalase↑, AntiTum↑, TumCP↓, angioG↓, Fas↑, FasL↑, ROS↑, ATM↑, P53↑, RB1↑, Casp9↑, Casp8↑, Casp3↓, BAX↑, Bcl-2↓, Bcl-xL↓, IAP1↓, XIAP↓, survivin↓, MMP2↓, MMP9↓, CycB/CCNB1↓, CDC25↓, CDC25↓, Cyt‑c↑, MMP↓, RenoP↑, mTOR↓, MDM2↓, LC3II↑, ERK↓, COX2↓, MMP3↓, TGF-β↓, EMT↑, ROCK1↓, FAK↓, RAS↓, Rho↓, NF-kB↓, uPA↓, MMP1↓, MMP13↓, ChemoSen↑,
451- CUR,    The effect of Curcumin on multi-level immune checkpoint blockade and T cell dysfunction in head and neck cancer
- vitro+vivo, HNSCC, SCC15 - vitro+vivo, HNSCC, SNU1076 - vitro+vivo, HNSCC, SNU1041
TumCMig↓, TumCG↓, PD-L1↓, PD-L2↓, Galectin-9↓, EMT↓, T-Cell↑, TILs↑, PD-1↓, TIM-3↓, CD4+↓, CD25+↓, FoxP3+↓, E-cadherin↑, CD8+↑, IFN-γ↑,
193- MFrot,  MF,    Rotating Magnetic Field Mitigates Ankylosing Spondylitis Targeting Osteocytes and Chondrocytes via Ameliorating Immune Dysfunctions
- in-vivo, Arthritis, NA
BMD↑, Cartilage↑, IL17↓, IL22↓, IL23↓, IL28↓, CD4+↓, CD8+↓, LAMB3↑, COL4↓, THBS2↓, ITGA11↓, PPARγ↑, ACAA1↓, PLIN1↓, FABP4↓, PCK1↓, UCP1↓, TNF-α↓,
4936- PEITC,    PEITC treatment suppresses myeloid derived tumor suppressor cells to inhibit breast tumor growth
- in-vivo, BC, MDA-MB-231
TumCG↓, CD34↓, CD11b↓, CSCs↓, ALC∅, CD4+↓, NF-kB↓, STAT3↓, Hif1a↓,
1282- RES,    Resveratrol Inhibits CD4+ T Cell Activation by Enhancing the Expression and Activity of Sirt1
- vitro+vivo, NA, NA
T-Cell↓, SIRT1↑, CD4+↓,

Showing Research Papers: 1 to 8 of 8

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 1,  

Mitochondria & Bioenergetics ⓘ

CDC25↓, 2,   MMP↓, 1,   UCP1↓, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis ⓘ

ACAA1↓, 1,   AMPK↑, 1,   FABP4↓, 1,   PCK1↓, 1,   PLIN1↓, 1,   PPARγ↑, 1,   SIRT1↑, 1,  

Cell Death ⓘ

Apoptosis↑, 1,   BAX↑, 1,   Bcl-2↓, 1,   Bcl-xL↓, 1,   Casp3↓, 1,   Casp8↑, 1,   Casp9↑, 1,   Cyt‑c↑, 1,   Fas↑, 1,   FasL↑, 1,   IAP1↓, 1,   MAPK↓, 1,   MDM2↓, 1,   survivin↓, 1,  

Transcription & Epigenetics ⓘ

other↓, 1,  

Autophagy & Lysosomes ⓘ

LC3II↑, 1,   TumAuto↑, 1,  

DNA Damage & Repair ⓘ

ATM↑, 1,   P53↑, 1,  

Cell Cycle & Senescence ⓘ

CycB/CCNB1↓, 1,   RB1↑, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

CD34↓, 1,   CSCs↓, 1,   EMT↓, 1,   EMT↑, 1,   ERK↓, 1,   mTOR↓, 1,   RAS↓, 1,   STAT3↓, 1,   TumCG↓, 3,  

Migration ⓘ

Cartilage↑, 1,   CD11b↓, 1,   COL4↓, 1,   E-cadherin↑, 1,   FAK↓, 1,   Galectin-9↓, 1,   ITGA11↓, 1,   LAMB3↑, 1,   MMP1↓, 1,   MMP13↓, 1,   MMP2↓, 1,   MMP3↓, 1,   MMP9↓, 1,   Rho↓, 1,   ROCK1↓, 1,   TGF-β↓, 1,   THBS2↓, 1,   Treg lymp↓, 2,   TumCI↓, 1,   TumCMig↓, 1,   TumCP↓, 1,   TumMeta↓, 1,   uPA↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   Hif1a↓, 1,  

Immune & Inflammatory Signaling ⓘ

CD25+↓, 4,   CD4+↓, 8,   COX2↓, 3,   FOXP3↓, 1,   FoxP3+↓, 4,   IFN-γ↑, 1,   IL1↓, 1,   IL17↓, 1,   IL22↓, 1,   IL23↓, 1,   IL28↓, 1,   IL4↓, 1,   IL4↑, 1,   IL6↓, 1,   Inflam↓, 1,   MCP1↓, 1,   NF-kB↓, 3,   PD-1↓, 1,   PD-L1↓, 1,   PD-L2↓, 1,   PGE2↓, 2,   T-Cell↓, 1,   T-Cell↑, 1,   TILs↑, 1,   TNF-α↓, 2,  

Cellular Microenvironment ⓘ

TIM-3↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,   ChemoSen↑, 1,   eff↑, 2,  

Clinical Biomarkers ⓘ

ALC∅, 1,   BMD↑, 1,   IL6↓, 1,   PD-L1↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   AntiTum↑, 1,   RenoP↑, 1,  

Infection & Microbiome ⓘ

CD8+↓, 1,   CD8+↑, 1,  
Total Targets: 106

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   Catalase↑, 1,   GPx↑, 1,   ROS↓, 1,  
Total Targets: 4

Scientific Paper Hit Count for: CD4+, CD4+ T Cells
3 Artemisinin
1 Berberine
1 Curcumin
1 Magnetic Field Rotating
1 Magnetic Fields
1 Phenethyl isothiocyanate
1 Resveratrol
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:544  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page